Table 1.
Patient characteristics
| All (n = 48) | Bev group (n = 17) | Non-Bev group (n = 31) | p value | |
|---|---|---|---|---|
| Age (years) | 67.5 (65.0–73.0) | 67.0 (66.0–73.0) | 68.0 (66.5–73.0) | 0.75 |
| Sex (male, %) | 40 (83.3) | 17 (100) | 23 (74.2) | 0.038 |
| Smoking status | 0.08 | |||
| Current or former | 42 (87.5) | 17 (100) | 25 (80.6) | |
| Never | 6 (12.5) | 0 (0) | 6 (19.4) | |
| Previous steroid therapy | 6 (12.5) | 2 (11.8) | 4 (12.9) | 1.00 |
| ECOG PS | 0.37 | |||
| 0–1 | 40 (83.3) | 13 (76.5) | 27 (87.1) | |
| ≥2 | 8 (16.7) | 4 (23.5) | 4 (12.9) | |
| Stage | 1.00 | |||
| III | 9 (18.7) | 3 (17.6) | 6 (19.4) | |
| IV | 39 (81.3) | 14 (82.4) | 25 (80.6) | |
| Classification of ILD | 1.00 | |||
| IIPs | 45 (93.7) | 16 (94.1) | 29 (93.5) | |
| Non-IIPs | 3 (6.3) | 1 (5.9) | 2 (6.5) | |
| ILD pattern | 1.00 | |||
| UIP pattern | 24 (50.0) | 9 (52.9) | 15 (48.4) | |
| Non-UIP pattern | 24 (50.0) | 8 (47.1) | 16 (51.6) | |
| SpO2 at rest (%) | 96.0 (96.0–97.0) | 96.0 (95.0–97.0) | 96.0 (96.0–97.0) | 0.43 |
| FVC (% predicted) | 88.5 (79.5–100) | 87.5 (78.5–99.5) | 90.0 (81.0–100) | 0.85 |
| LDH (U/L) | 220.0 (194.8–254.0) | 228.0 (205.0–253.0) | 211.0 (194.5–252.5) | 0.48 |
| KL-6 (U/ml) | 800.0 (518.5–1190.0) | 828.5 (591.0–1311.0) | 778.0 (454.0–1120.0) | 0.27 |
| CRP (mg/dl) | 0.9 (0.3–2.0) | 0.9 (0.7–2.3) | 0.9 (0.2–1.2) | 0.44 |
| First-line regiments | 0.96 | |||
| CDDP + PEM | 11 (22.9) | 4 (23.5) | 7 (22.6) | |
| CBDCA + PEM | 25 (52.1) | 10 (58.8) | 15 (48.3) | |
| PEM | 4 (8.3) | 1 (5.9) | 3 (9.7) | |
| CBDCA + PTX | 8 (16.7) | 2 (11.8) | 6 (19.4) | |
| PEM-containing regiments | 40 (83.3) | 15 (88.2) | 25 (80.6) | 0.69 |
| First-line related AE-ILD | 7 (14.5) | 0 (0) | 7 (22.6) | 0.041 |
Data are expressed as group median (interquartile range) or number of patients (%). The p values refer to comparisons between the Bev and non-Bev groups. ECOG PS Eastern Cooperative Oncology Group performance status, ILD interstitial lung disease, IIPs idiopathic interstitial pneumonias, UIP usual interstitial pneumonia, FVC forced vital capacity, SpO2 percutaneous oxygen saturation, LDH lactate dehydrogenase, KL-6 Krebs von den Lungen-6, CRP C-reactive protein, CDDP cisplatin, PEM pemetrexed, CBDCA carboplatin, PTX paclitaxel, AE-ILD acute exacerbation of interstitial lung disease